News

  • 20 October 2020

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and leader in NOX therapies, today announced that its lead drug candidate, setanaxib, has been granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of primary biliary cholangitis (PBC). 

  • 8 October 2020

    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead asset, mavorixafor, for the treatment of adult patients with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene.

  • 7 October 2020

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announced that Raymond W. Cohen, CEO of Axonics, has been named an Ernst & Young Entrepreneur of the Year 2020 Award winner for the Pacific Southwest, Orange County. The Entrepreneur of the Year program honors entrepreneurial business leaders whose vision fosters innovation, growth and prosperity as they build and sustain successful businesses. The award was announced through the program’s first-ever virtual awards gala on October 6, 2020.

  • 5 October 2020

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced survey results of 137 patients previously implanted with the Medtronic InterStim II ™ that are now being treated with the Axonics r-SNM System.

  • 24 September 2020

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has made the decision to institute a review regarding the validity of six Medtronic patents that Axonics is contesting.